Research programme: respiratory disorders therapies - Kos Pharmaceuticals

Drug Profile

Research programme: respiratory disorders therapies - Kos Pharmaceuticals

Alternative Names: KI 03219; KI 04204

Latest Information Update: 04 Mar 2008

Price : $50

At a glance

  • Originator Kos Pharmaceuticals
  • Class
  • Mechanism of Action Beta-adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
  • 25 Aug 2006 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
  • 25 Aug 2006 Preclinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top